Aldebaran Capital LLC Sells 7,050 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Aldebaran Capital LLC cut its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 262,753 shares of the company’s stock after selling 7,050 shares during the quarter. Amylyx Pharmaceuticals accounts for 0.9% of Aldebaran Capital LLC’s holdings, making the stock its 22nd biggest position. Aldebaran Capital LLC’s holdings in Amylyx Pharmaceuticals were worth $993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of AMLX. Blue Trust Inc. increased its stake in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after purchasing an additional 4,883 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $45,000. RPO LLC acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter worth $46,000. EntryPoint Capital LLC bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth about $53,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Amylyx Pharmaceuticals in the fourth quarter valued at about $56,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.33.

Insider Activity

In related news, CEO Joshua B. Cohen sold 21,490 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $74,570.30. Following the completion of the transaction, the chief executive officer now owns 3,355,280 shares of the company’s stock, valued at approximately $11,642,821.60. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the completion of the sale, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,980 shares of company stock worth $252,769 over the last ninety days. Insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 7.1 %

AMLX stock opened at $3.51 on Friday. The stock has a market cap of $310.99 million, a PE ratio of -0.92 and a beta of -0.51. The stock has a 50-day moving average price of $3.55 and a two-hundred day moving average price of $4.05. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. On average, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.